Growth in 'patient-centric care' driving M&A in pharma supply chains
An explosion in M&A activity surrounding “patient-centric” approaches to healthcare is set to further reshape ...
© Peter Scott
US pharma bosses are considering moving their production home, which could have far-reaching consequences for global pharma supply chains. The obstacles are challenging, though.
Last week pharma giant Eli Lilly announced plans to spend at least $27bn on the construction of four new manufacturing facilities in the US. Three, set to come onstream over the coming five years, will be turning out raw ingredients for pharma manufacture, while the fourth will produce injectable medicines.
The company ...
Comment on this article